Heng Chen1, Xingang Sun1, Chengui Zhuo2, Jianqiang Zhao3, Aohan Zu1, Qiqi Wang1, Liangrong Zheng1. 1. Department of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China. 2. Department of Cardiology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, People's Republic of China. 3. Department of Cardiology, The Fourth Affiliated Hospital, College of Medicine, Zhejiang University, Yiwu, People's Republic of China.
Abstract
PURPOSE: Cardiac troponin I (cTnI) is a well-established biomarker for stroke prediction, especially in patients with heart diseases. However, the causal effect of circulating cTnI on stroke remains unclear. METHODS: We employed Mendelian Randomization (MR) analysis to determine the associations between genetically predicted circulating cTnI levels and stroke and its subtypes. Summary-level data for exposure and outcomes were generated from different genome-wide association studies. Single-nucleotide polymorphisms (SNPs) associated with circulating cTnI at genome-wide significance level (P < 5 × 10-8) were employed as instrumental variables (IVs). We used fixed-effect inverse-variance weighted (IVW) as the main method for pooling MR estimates. Sensitivity analyses and multivariable MR analyses were carried out to assess the robustness of the results. RESULTS: Using the fixed-effects IVW method, we found that genetically elevated plasma cTnI levels may have a causal effect on the risk of cardioembolic stroke (CES) (odds ratio (OR), 1.58; 95% confidence interval (CI), 1.17-2.13; P = 0.003). Additional analyses including multiplicative random-effects (mre) IVW, weighted median, MR-Egger and MR-PRESSO yielded similar results, but with broader CIs that span 1.0. The total effect of cTnI on CES was attenuated by adjusting for the effect of atrial fibrillation (OR,1.26; 95% CI, 0.76-2.11; P = 0.371) and smoking (OR,1.53; 95% CI, 0.87-2.66; P = 0.137). In addition, we found no causal effect of cTnI on the risk of any stroke and other stroke subtypes, including any ischemic stroke, large artery stroke, cardioembolic stroke, small vessel stroke, and intracerebral hemorrhage. These results were consistent across sensitivity analyses. CONCLUSION: This study provides little evidence that increased serum cTnI levels lead to a higher risk of stroke.
PURPOSE: Cardiac troponin I (cTnI) is a well-established biomarker for stroke prediction, especially in patients with heart diseases. However, the causal effect of circulating cTnI on stroke remains unclear. METHODS: We employed Mendelian Randomization (MR) analysis to determine the associations between genetically predicted circulating cTnI levels and stroke and its subtypes. Summary-level data for exposure and outcomes were generated from different genome-wide association studies. Single-nucleotide polymorphisms (SNPs) associated with circulating cTnI at genome-wide significance level (P < 5 × 10-8) were employed as instrumental variables (IVs). We used fixed-effect inverse-variance weighted (IVW) as the main method for pooling MR estimates. Sensitivity analyses and multivariable MR analyses were carried out to assess the robustness of the results. RESULTS: Using the fixed-effects IVW method, we found that genetically elevated plasma cTnI levels may have a causal effect on the risk of cardioembolic stroke (CES) (odds ratio (OR), 1.58; 95% confidence interval (CI), 1.17-2.13; P = 0.003). Additional analyses including multiplicative random-effects (mre) IVW, weighted median, MR-Egger and MR-PRESSO yielded similar results, but with broader CIs that span 1.0. The total effect of cTnI on CES was attenuated by adjusting for the effect of atrial fibrillation (OR,1.26; 95% CI, 0.76-2.11; P = 0.371) and smoking (OR,1.53; 95% CI, 0.87-2.66; P = 0.137). In addition, we found no causal effect of cTnI on the risk of any stroke and other stroke subtypes, including any ischemic stroke, large artery stroke, cardioembolic stroke, small vessel stroke, and intracerebral hemorrhage. These results were consistent across sensitivity analyses. CONCLUSION: This study provides little evidence that increased serum cTnI levels lead to a higher risk of stroke.
Authors: Yader Sandoval; Richard Nowak; Christopher R deFilippi; Robert H Christenson; W Frank Peacock; James McCord; Alexander T Limkakeng; Anne Sexter; Fred S Apple Journal: J Am Coll Cardiol Date: 2019-07-23 Impact factor: 24.094
Authors: Sumeet S Chugh; Rasmus Havmoeller; Kumar Narayanan; David Singh; Michiel Rienstra; Emelia J Benjamin; Richard F Gillum; Young-Hoon Kim; John H McAnulty; Zhi-Jie Zheng; Mohammad H Forouzanfar; Mohsen Naghavi; George A Mensah; Majid Ezzati; Christopher J L Murray Journal: Circulation Date: 2013-12-17 Impact factor: 29.690
Authors: Ziad Hijazi; Johan Lindbäck; John H Alexander; Michael Hanna; Claes Held; Elaine M Hylek; Renato D Lopes; Jonas Oldgren; Agneta Siegbahn; Ralph A H Stewart; Harvey D White; Christopher B Granger; Lars Wallentin Journal: Eur Heart J Date: 2016-02-25 Impact factor: 29.983
Authors: Jack Bowden; Fabiola Del Greco M; Cosetta Minelli; George Davey Smith; Nuala Sheehan; John Thompson Journal: Stat Med Date: 2017-01-23 Impact factor: 2.373
Authors: Gibran Hemani; Jie Zheng; Benjamin Elsworth; Tom R Gaunt; Philip C Haycock; Kaitlin H Wade; Valeriia Haberland; Denis Baird; Charles Laurin; Stephen Burgess; Jack Bowden; Ryan Langdon; Vanessa Y Tan; James Yarmolinsky; Hashem A Shihab; Nicholas J Timpson; David M Evans; Caroline Relton; Richard M Martin; George Davey Smith Journal: Elife Date: 2018-05-30 Impact factor: 8.140